Determination of 5-fluorouracil in human plasma by high-performance liquid chromatography (HPLC)

Abstract

5-Fluorouracil (5-FU) has a broad spectrum of anti-tumor activity, widely applied to the treatment of cancers. However, it is necessary to determine the plasma concentration of 5-FU in clinical practice due to its narrow therapeutic index. Therefore, a simple, economic and sensitive high-performance liquid chromatography (HPLC) method was developed and validated for the determination of 5-FU in human plasma. Ethyl acetate was chosen as extraction reagent. Chromatographic separation was performed on a Diamonsil C18 column (250 mm × 4.6 mm i.d., 5 μm) with the mobile phase consisting of methanol and 20 mmol/L ammonium formate using a linear gradient elution at a flow rate of 0.8 mL/min. 5-FU and 5-bromouracil (5-BU) were detected by UV detector at 265 nm. The calibration curve was linear over the concentration range of 5–500 ng/mL and the correlation coefficient was not less than 0.992 6 for all calibration curves. The intra- and inter-day precisions were less than 10.5% and 4.3%, respectively, and the accuracy was within ±3.7%. The recovery at all concentration levels was 80.1±8.6%. 5-FU was stable under possible conditions of storing and handling. This method is proved applicable to therapeutic drug monitoring and pharmacokinetic studies of 5-FU in human.

Keywords

5-fluorouracil(5-FU) / high-performance liquid chromatography (HPLC) / human plasma

References

[1] Sobrero A. F., Aschele C., Bertino J. R. Fluorouracil in colorectal cancer—A tale of two drugs: Implications for biochemical modulation[J]. Journal of Clinical Oncology, 1997, 15(1): 368-381.

[2] Longley D. B., Harkin D. P., Johnston P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies[J]. Nat Rev Cancer, 2003, 3(5): 330-338.

[3] Diasio R. B., Harris B. E. Clinical pharmacology of 5-fluorouracil[J]. Clinical Pharmacokinetics, 1989, 16(4): 215-237.

[4] Di Paolo A., Danesi R., Ciofi L., et al. Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling[J]. Ther Drug Monit, 2005, 27(3): 362-368.

[5] Bates C. D., Watson D. G., Willmott N., et al. The analysis of 5-fluorouracil in human plasma by gas chromatographynegative ion chemical ionization mass spectrometry (GCNICIMS) with stable isotope dilution[J]. J Pharmt Biomed Anal, 1991, 9(1): 19-21.

[6] De Leenheer A. P., Cosyns-Duyck M. C. Flame-ionization GLC assay for fluorouracil in plasma of cancer patients[J]. J Pharmt Sci, 1979, 68(9): 1174-1176.

[7] De Bruin E. A., Tjaden U. R., Van Oosterom A. T., et al. Determination of the underivatized antineoplastic drugs cyclophosphamide and 5-fluorouracil and some of their metabolites by capillary gas chromatography combined with electron-capture and nitrogen-phosphorus selective detection[J]. J Chromatogr, 1983, 279 603-608.

[8] Joulia J. M., Pinguet F., Grosse P. Y., et al. Determination of 5-fluorouracil and its main metabolites in plasma by highperformance liquid chromatography: Application to a pharmacokinetic study[J]. J Chromatogr B Biomed Sci Appl, 1997, 692(2): 427-435.

[9] Hills E. B., Godefroi V. C., O’Leary I. A., et al. GLC determination for ftorafur in biological fluids[J]. J Pharm Sci, 1977, 66(10): 1497-1499.

[10] Kawabata N., Sugiyama S., Kuwamura T., et al. Simultaneous determination of tegafur and 5-fluorouracil in serum by GLC using nitrogen-sensitive detection[J]. J Pharm Sci, 1983, 72(10): 1162-1165.

[11] Wu A. T., Schwandt H. J., Finn C., et al. Determination of ftorafur and 5-fluorouracil levels in plasma and urine[J]. Res Commun Chem Pathol Pharmacol, 1976, 14(1): 89-102.

[12] Iwamoto M., Yoshida S., Hirose S. Fluorescence determination of 5-fluorouracil and 1-(tetrahydro-2-furanyl)-5-fluorouracil in blood serum by high-performance liquid chromatography[J]. J Chromatogr, 1984, 310(1): 151-157.

[13] Jarugula V. R., Boudinot F. D. High-performance liquid chromatographic determination of 5-fluorouracil and its prodrugs, tegafur and 4-deoxy-5-fluorouracil, in rat plasma[J]. J Chromatogr B Biomed Sci Appl, 1996, 677(1): 199-203.

[14] Zufia L., Aldaz A., Castellanos C., et al. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: Validation for application in clinical pharmacokinetic studies[J]. Ther Drug Monit, 2003, 25(2): 221-228.

[15] Maring J. G., Schouten L., Greijdanus B., et al. A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma[J]. Ther Drug Monit, 2005, 27(1): 25-30.

[16] Matsushima E., Yoshida K., Kitamura R., et al. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using highperformance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry[J]. J Chromatogr B Biomed Sci Appl, 1997, 691(1): 95-104.

[17] Chu D., Gu J., Liu W., et al. Sensitive liquid chromatographic assay for the simultaneous determination of 5-fluorouracil and its prodrug, tegafur, in beagle dog plasma[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 795(2): 377-382.

[18] Ciccolini J., Mercier C., Blachon M. F., et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity[J]. J Clin Pharm Ther, 2004, 29(4): 307-315.

[19] Bocci G., Danesi R., Di Paolo A. D., et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients[J]. Clin Cancer Res, 2000, 6(8): 3032-3037.

[20] Pisano R., Breda M., Grassi S., et al. Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues[J]. J Pharm Biomed Anal, 2005, 38(4): 738-745.

[21] Kosovec J. E., Egorin M. J., Gjurich S., et al. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry[J]. Rapid Commun Mass Spectrom, 2008, 22(2): 224-230.

[22] van Kuilenburg A. B., van Lenthe H., Maring J. G., et al. Determination of 5-fluorouracil in plasma with HPLC-tandem mass spectrometry[J]. Nucleosides Nucleotides Nucleic Acids, 2006, 25(9–11): 1257-1260.

[23] Remaud G., Boisdron-Celle M., Morel A., et al. Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 824(1/2): 153-160.

[24] Gamelin E., Boisdron-Celle M., Turcant A., et al. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma[J]. J Chromatogr B Biomed Sci Appl, 1997, 695(2): 409-416.

[25] Oshima T., Yamada R., Hatori S., et al. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer[J]. Oncol Rep, 2006, 16(2): 361-366.

[26] Peters G. J., Noordhuis P., van Kuilenburg A. B., et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0. 4:1) in patients with solid tumors[J]. Cancer Chemother Pharmacol, 2003, 52(1): 1-12.

[27] Siethoff C., Orth M., Ortling A., et al. Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry[J]. J Mass Spectrom, 2004, 39(8): 884-889.